Abstract
CD109 is a glycosylphosphatidylinositol (GPI)-anchored glycoprotein, whose expression is upregulated in squamous cell carcinomas of the lung, esophagus, uterus and oral cavity. CD109 negatively regulates transforming growth factor (TGF)-β signaling in keratinocytes by directly modulating receptor activity. In this study, we further characterized CD109 regulation of TGF-β signaling and cell proliferation. We found that CD109 is produced as a 205 kDa glycoprotein, which is then processed in the Golgi apparatus into 180 kDa and 25 kDa proteins by furin (furinase). 180 kDa CD109 associated with GPI-anchored 25 kDa CD109 on the cell surface and was also secreted into the culture medium. To investigate whether furinase cleavage of CD109 is necessary for its biological activity, we mutated arginine 1273 in the CD109 furinase cleavage motif (amino acid 1270-RRRR-1273) to serine (R1273S). Interestingly, CD109 R1273S neither significantly impaired TGF-β signaling nor affected TGF-β-mediated suppression of cell growth, although it was expressed on the cell surface as a 205 kDa protein. Consistent with this finding, the 180 kDa and 25 kDa CD109 complex, but not CD109 R1273S, associated with the type I TGF-β receptor. These findings indicate that processing of CD109 into 180 kDa and 25 kDa proteins by furin, followed by complex formation with the type I TGF-β receptor is required for the regulation of TGF-β signaling in cancer cells and keratinocytes.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Arnold JN, Wallis R, Willis AC, Harvey DJ, Royle L, Dwek RA et al. (2006). Interaction of mannan binding lectin with α2 macroglobulin via exposed oligomannose glycans. A conversed feature of the thiol ester protein family. J Biol Chem 281: 6955–6963.
Bierie B, Moses HL . (2006). Tumour microenvironment: TGFβ: the molecular Jekyll and Hyde of cancer. Nat Rev Cancer 6: 506–520.
Dennler S, Goumans MJ, Ten Dijke P . (2002). Transforming growth factor beta signal transduction. J Leukoc Biol 71: 731–740.
Derynck R, Akhurst RJ, Balmain A . (2001). TGF-β signaling in tumor suppression and cancer progression. Nat Genet 29: 117–129.
Dubois CM, Laprise MH, Blanchette F, Gentry LE, Leduc R . (1995). Processing of transforming growth factor beta 1 precursor by human furin convertase. J Biol Chem 270: 10618–10624.
Finnson KW, Tam BY, Liu K, Marcoux A, Lepage P, Roy S et al. (2006). Identification of CD109 as part of the TGF-β receptor system in human keratinocytes. FASEB J 20: 1525–1527.
Garcia M, Mirre C, Quaroni A, Reggio H, Le Bivic A . (1993). GPI-anchored proteins associate to form microdomains during their intracellular transport in Caco-2 cells. J Cell Sci 104: 1281–1290.
Gentry LE, Nash BW . (1990). The pro-domain of pre-pro-transforming growth factor beta 1 when independently expressed is a functional binding protein for the mature growth factor. Biochemistry 29: 6851–6857.
Giesert C, Marxer A, Sutherland DR, Schuh AC, Kanz L, Bürring HJ . (2003). Antibody W7C5 defines a CD109 epitope expressed on CD34+ and CD34- hematopoietic and mesenchymal stem cell subsets. Ann NY Acad Sci 996: 227–230.
Guarnaccia SP, Shaper JH, Schnaar RL . (1983). Tunicamycin inhibits ganglioside biosynthesis in neuronal cells. Proc Natl Acad Sci USA 80: 1551–1555.
Hagiwara S, Murakumo Y, Sato T, Shigetomi T, Mitsudo K, Tohnai I et al. (2008). Up-regulation of CD109 expression is associated with carcinogenesis of the squamous epithelium of the oral cavity. Cancer Sci 99: 1916–1923.
Haregewoin A, Solomon K, Hom RC, Soman G, Bergelson JM, Bhan AK et al. (1994). Cellular expression of a GPI-linked T cell activation protein. Cell Immunol 156: 357–370.
Hasegawa M, Hagiwara S, Sato T, Jijiwa M, Murakumo Y, Maeda M et al. (2007). CD109, a new marker for myoepithelial cells of mammary, salivary, and lacrimal glands and prostate basal cells. Pathol Int 57: 245–250.
Hasegawa M, Moritani S, Murakumo Y, Sato T, Hagiwara S, Suzuki C et al. (2008). CD109 expression in basal-like breast carcinoma. Pathol Int 58: 288–294.
Hashimoto M, Ichihara M, Watanabe T, Kawai K, Koshikawa K, Yuasa N et al. (2004). Expression of CD109 in human cancer. Oncogene 23: 3716–3120.
Jakowlew SB . (2006). Transforming growth factor-β in cancer and metastasis. Cancer Metastasis Rev 25: 435–457.
Kelton JG, Smith JW, Horsewood P, Humbert JR, Hayward CP, Warkentin TE . (1990). Gova/b alloantigen system on human platelets. Blood 75: 2172–2176.
Leivonen SK, Kähäri VM . (2007). Transforming growth factor-β signaling in cancer invasion and metastasis. Int J Cancer 121: 2119–2124.
Lin M, Sutherland DR, Horsfall W, Totty N, Yeo E, Nayar R et al. (2002). Cell surface antigen CD109 is a novel member of the α2 macroglobulin/C3, C4, C5 family of thioester-containing proteins. Blood 99: 1683–1691.
Massagué J, Seoane J, Wotton D . (2005). Smad transcription factors. Genes Dev 19: 2783–2810.
Molloy SS, Bresnahan PA, Leppla SH, Klimpel KR, Thomas G . (1992). Human furin is a calcium-dependent serine endoprotease that recognizes the sequence Arg-X-X-Arg and efficiently cleaves anthrax toxin protective antigen. J Biol Chem 267: 16396–16402.
Moustakas A, Pardali K, Gaal A, Heldin CH . (2002). Mechanisms of TGF-βsignaling in regulation of cell growth and differentiation. Immunol Lett 82: 85–91.
Murray LJ, Bruno E, Uchida N, Hoffman R, Nayar R, Yeo EL et al. (1999). CD109 is expressed on a subpopulation of CD34+ cells enriched in hematopoietic stem and progenitor cells. Exp Hematol 27: 1282–1294.
Nakayama K . (1997). Furin: a mammalian subtilisin/Kex2p-like endoprotease involved in processing of a wide variety of precursor proteins. Biochem J 327: 625–635.
Ouweland AM, Duijnhoven HL, Keizer GD, Dorssers LC, Ven WJ . (1990). Structural homology between the human fur gene product and the subtilisin-like protease encoded by yeast KEX2. Nucleic Acids Res 18: 664.
Pardali K, Moustakas A . (2007). Actions of TGF-β as tumor suppressor and pro-metastatic factor in human cancer. Biochim et Biophysi Acta 1775: 21–62.
Rouillé Y, Duguay SJ, Lund K, Furuta M, Gong Q, Lipkind G et al. (1995). Proteolytic processing mechanism in the biosynthesis of neuroendocrine peptides: the subtilisin-like proprotein convertases. Front Neuroendocrinol 16: 322–361.
Sato T, Murakumo Y, Hagiwara S, Jijiwa M, Suzuki C, Yatabe Y et al. (2007). High-level expression of CD109 is frequently detected in lung squamous cell carcinomas. Pathol Int 57: 719–724.
Shi Y, Massagué J . (2003). Mechanisms of TGF-beta signaling from cell membrane to the nucleus. Cell 113: 685–700.
Steiner DF . (1998). The proprotein convertases. Curr Opin Chem Biol 2: 31–39.
Struck DK, Lennarz WJ . (1977). Evidence for the participation of saccharide-lipids in the synthesis of the oligosaccharide chain of ovalbumin. J Biol Chem 252: 1007–1013.
Sutherland DR, Yeo E, Ryan A, Mills GB, Bailey D, Baker MA . (1991). Identification of a cell-surface antigen associated with activated T lymphoblasts and activated platelets. Blood 77: 84–93.
Takatsuki A, Arima K, Tamura G . (1971). Tunicamycin. a new antibiotic. I. Isolation and characterization of tunicamycin. J Antibiot 24: 215–223.
Tam BY, Finnson KW, Philip A . (2003). Glycosylphosphatidylinositol-anchored proteins regulate transforming growth factor-β signaling in human keratinocytes. J Biol Chem 278: 49610–49617.
Thomas G . (2002). Furin at the cutting edge: from protein traffic to embryogenesis and disease. Nat Rev Mol Cell Biol 3: 753–766.
Waechter CJ, Harford JB . (1977). Evidence for the enzymatic transfer of N-acetylglucosamine from UDP-N-acetylglucosamine into dolichol derivative and glycoproteins by calf brain membranes. Arch Biochem Biophys 181: 185–198.
Wakefield LM, Roberts AB . (2002). TGF-β signaling: positive and negative effects on tumorigenesis. Curr Opin Genet Dev 12: 22–29.
Wang X, Sun W, Bai J, Ma L, Yu Y, Geng J et al. (2009). Growth inhibition induced by transforming growth factor-β1 in human oral squamous cell carcinoma. Mol Biol Rep 36: 861–869.
Xu X, Brodie SG, Yang X, Im YH, Parks WT, Chen L et al. (2000). Haploid loss of the tumor suppressor Smad4/Dpc4 initiates gastric polyposis and cancer in mice. Oncogene 19: 1868–1874.
Zhang JM, Hashimoto M, Kawai K, Murakumo Y, Sato T, Ichihara M et al. (2005). CD109 expression in squamous cell carcinoma of the uterine cervix. Pathol Int 55: 165–169.
Acknowledgements
This work was supported by Grants-in-Aid for Global Center of Excellence (GCOE) research, Scientific Research (A) and Scientific Research on Priority Area ‘Cancer’ commissioned by the Ministry of Education, Culture, Sports, Science and Technology (MEXT) of Japan (to MT).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Additional information
Supplementary Information accompanies the paper on the Oncogene website
Supplementary information
Rights and permissions
About this article
Cite this article
Hagiwara, S., Murakumo, Y., Mii, S. et al. Processing of CD109 by furin and its role in the regulation of TGF-β signaling. Oncogene 29, 2181–2191 (2010). https://doi.org/10.1038/onc.2009.506
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/onc.2009.506
Keywords
This article is cited by
-
The GPI-anchored protein CD109 protects hematopoietic progenitor cells from undergoing erythroid differentiation induced by TGF-β
Leukemia (2022)
-
CD109 expression in tumor cells and stroma correlates with progression and prognosis in pancreatic cancer
Virchows Archiv (2022)
-
ZNF507 affects TGF-β signaling via TGFBR1 and MAP3K8 activation in the progression of prostate cancer to an aggressive state
Journal of Experimental & Clinical Cancer Research (2021)
-
CD109 mediates tumorigenicity and cancer aggressiveness via regulation of EGFR and STAT3 signalling in cervical squamous cell carcinoma
British Journal of Cancer (2020)
-
CD109 acts as a gatekeeper of the epithelial trait by suppressing epithelial to mesenchymal transition in squamous cell carcinoma cells in vitro
Scientific Reports (2019)